Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China

Abstract Background Clinical trials have demonstrated the efficacy of edaravone dexborneol in the treatment of acute ischemic stroke. This study aims to determine the cost-effectiveness of edaravone dexborneol compared with human urinary kallidinogenase from China’s healthcare system perspective. Me...

Full description

Bibliographic Details
Main Authors: Pingyu Chen, Mengjie Luo, Yanqiu Chen, Yanlei Zhang, Chao Wang, Hongchao Li
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Health Economics Review
Subjects:
Cost Effectiveness
Edaravone dexborneol
Human urinary kallidinogenase
Acute ischemic stroke
Matching adjusted indirect comparison
Online Access:https://doi.org/10.1186/s13561-024-00479-6

Internet

https://doi.org/10.1186/s13561-024-00479-6

Similar Items